Ryan McDonald

Ryan McDonald, Associate Editorial Director for CURE®, has been with the team since February 2020 and has previously covered medical news across several specialties prior to joining MJH Life Sciences. He is a graduate of Temple University, where he studied journalism and minored in political science and history. He considers himself a craft beer snob and would like to open a brewery in the future. During his spare time, he can be found rooting for all major Philadelphia sports teams. Follow Ryan on Twitter @RMcDonald11 or email him at rmcdonald@curetoday.com.

Calquence Linked to Fewer Heart-Related, Other Toxicities in Patients With CLL Than Imbruvica

January 07, 2022

Treatment with Calquence resulted in fewer toxicities, including atrial fibrillation, flutter and hypertension, in patients with previously treated chronic lymphocytic leukemia, compared with Imbruvica treatment, according to findings from the analysis of a phase 3 trial.

Novel Drug Has Potential to ‘Become New Standard of Care’ in Advanced, ER-Positive Breast Cancer

December 08, 2021

The use of elacestrant, an investigational therapy, elicited a 30% reduction in the risk of disease progression or death compared with standard of care in a group of patients with estrogen receptor (ER)–positive, HER2-negative metastatic breast cancer.

After The Dust Settled: Retired NYC Firefighter Remembers 9/11 After Lung Cancer Journey

September 11, 2021

A retired New York City firefighter recalls his return to the city he once served for more than three decades on the day prior to the 9/11 terrorist attacks and all that followed, including his several bouts with lung cancer years after the dust had settled.

Investigational Cancer Treatment Being Evaluated in B-Cell Malignancies

August 23, 2021

Researchers are evaluating the safety and efficacy of zandelisib, an investigational cancer therapy, for the treatment of patients with marginal zone lymphoma and follicular lymphoma who have received at least two prior therapies.

Patient Recruitment Has Begun for Trial Assessing Cosela in Metastatic Bladder Cancer

August 20, 2021

Preliminary results of the phase 2 trial assessing the safety and efficacy of Cosela with gemcitabine/platinum-based chemotherapy and Bavencio maintenance therapy for metastatic bladder cancer are expected to be released in the second half of 2022.

High Volume of Vitamin D Intake Linked to Decreased Early-Onset Colon Cancer Risk

August 17, 2021

People who meet regular dietary recommendations and the minimum daily requirement for vitamin D intake may experience a protection against early-onset colon cancer, according to an expert from the Dana-Farber Cancer Institute.

The Toughest Race of His Life

July 09, 2021

More than nine hours of surgery to remove a rare form of bone cancer in the his hip and leg forced Colin Jackson to relearn how to do simple tasks. Months later, he crossed the finish line of a marathon.

Rapid Evolution in Melanoma Treatment Landscape Over Past Decade Has Significantly Benefitted Patients, Expert Says

July 07, 2021

Patients with melanoma are living longer than ever before and some, according to an expert from the Rutgers Cancer Institute of New Jersey, are even getting cured or achieving long-term remissions thanks to developments in the treatment landscape.